艾滋病相关非霍奇金淋巴瘤的治疗研究进展

Research progress in the treatment of AIDS-related non-Hodgkin lymphoma

非霍奇金淋巴瘤(NHL)是艾滋病相关恶性肿瘤疾病中最为常见的一种。联合抗逆转录病毒疗法(cART)可使HIV感染者获得免疫重建,提升对化疗的耐受能力,且多数患者可从中获益。艾滋病相关NHL具有高度异质性,临床表现多样,发病机制较为复杂,治疗困难。近年来,大量临床试验及前瞻性研究数据得以更新,分子学及肿瘤基因组学、免疫学等各类新技术研究不断深入,为艾滋病相关NHL的治疗提供了新思路。本文主要对其几个亚型在治疗策略及新药物研究中的进展作一综述。

Non-Hodgkin lymphoma(NHL)is one of the most common AIDS-related malignancies.The combined retrovirus therapy(cART)could improve immune reconstitution and chemotherapy tolerance in HIV-infected patients,and most patients can benefit from it.Due to its high heterogeneity,diverse clinical manifestations and complex pathogenesis,AIDSrelated NHL is difficult to treat.In recent years,a large number of clinical trials and prospective studies have been updated,and new technologies such as molecular,tumor genomics and immunology have been further studied,all of which provide new ideas for the treatment of AIDS-related NHL.This article reviewed the progress of several subtypes of AIDS-related NHL in the research of therapeutic strategies and new drugs.